Showing 5021-5030 of 5806 results for "".
- Parent-supplied Photos May Allow Pediatric Derms to Make Virtual Diagnoseshttps://practicaldermatology.com/news/parent-supplied-photos-may-allow-pediatric-derms-to-make-virtual-diagnoses/2457968/Parent-supplied photos taken via smartphone cameras can allow pediatric dermatologists to make a diagnosis without an office visit in many cases, new research shows. This finding, which appear in JAMA Dermatology, suggest that direct-to-patient dermatology can accurate
- Ortho Dermatologics Announces Aspire Higher Scholarship Honoreeshttps://practicaldermatology.com/news/ortho-dermatologics-announces-aspire-higher-scholarship-honorees/2457972/Ortho Dermatologics announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or fou
- Isdin Introduces Two New Productshttps://practicaldermatology.com/news/isdin-introduces-two-new-products/2457977/ISDIN is rolling out ISDIN Age Contour plus a new shade in their ISDINCEUTICS Skin Drops collection. ISDIN AGE CONTOUR is a triple-action face and neck cream that aims to reduce jawline sagging and glycation in the skin as well as protect&nb
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- DermTech Adds Dr. Harold Rabinovitz to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-harold-rabinovitz-to-scientific-advisory-board/2457982/DermTech, Inc., appointed Harold Rabinovitz, MD to its Scientific Advisory Board. Dr. Rabinovitz is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.</
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Save the Dates: eRelevance Launches National Marketing Education Tour for Aesthetic Healthcare Practiceshttps://practicaldermatology.com/news/erelevance-launches-national-marketing-education-tour-for-aesthetic-healthcare-practices/2457983/eRelevance Corporation announced the expansion of its popular marketing education workshops to more cities nationwide. The workshops help aesthetic healthcare providers understand the significant opportunity in marketing to their existing patient
- New from Jergens: Nourishing Honey Dry Skin Moisturizerhttps://practicaldermatology.com/news/new-from-jergens-nourishing-honey-dry-skin-moisturizer/2457984/Jergens is launching their new Nourishing Honey Dry Skin Moisturizer. Formulated with antioxidant-packed Orange Blossom Honey, which is known to contain potent antibacterial and anti-inflammatory properties, the new Jergens® Nouri
- Dermatomyositis Breakthrough? Drug reduces disease burden in patients with skin-predominant DMhttps://practicaldermatology.com/news/dermatomyositis-breakthrough-drug-reduces-disease-burden-in-patients-with-skin-predominant-dm/2457990/A new treatment for dermatomyositis (DM) may reduce the severity of the disease in patients whose DM was resistant to other therapies. As part of a randomized, double-blind study conducted at the Perelman School of Medicine at the University of Pennsyl
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by